A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

NCT03830411 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Nonsquamous Non-Small Cell Lung Cancer

Interventions

DRUG: Sintilimab
DRUG: Docetaxel
DRUG: Pemetrexed

Sponsor

Xin-Hua Xu